Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".
作者信息
Pappagallo Marco, Inturrisi Charles E, Manfredi Paolo L
机构信息
Relmada Therapeutics, Inc., 2222 Ponce de Leon Blvd. Floor 3, Coral Gables, FL, 33134, USA.
出版信息
CNS Drugs. 2022 Feb;36(2):203-204. doi: 10.1007/s40263-021-00891-0. Epub 2022 Jan 11.
Abstract
摘要
相似文献
1
Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".关于“用于治疗情绪障碍的新型谷氨酸能调节剂：现状”的评论
CNS Drugs. 2022 Feb;36(2):203-204. doi: 10.1007/s40263-021-00891-0. Epub 2022 Jan 11.
2
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.新型谷氨酸能调节剂治疗心境障碍的研究进展
CNS Drugs. 2021 May;35(5):527-543. doi: 10.1007/s40263-021-00816-x. Epub 2021 Apr 26.
3
Authors' Reply to Pappagallo et al.: Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".作者对帕帕加洛等人的回复：对“用于治疗情绪障碍的新型谷氨酸能调节剂：现状”的评论
CNS Drugs. 2022 Feb;36(2):205-206. doi: 10.1007/s40263-021-00892-z. Epub 2022 Jan 11.
4
Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets.心境障碍中谷氨酸能调节异常：发现新型药物靶点的机会。
Expert Opin Ther Targets. 2020 Dec;24(12):1187-1209. doi: 10.1080/14728222.2020.1836160. Epub 2020 Nov 3.
5
[Glutamatergic conception of mood disorders].[情绪障碍的谷氨酸能概念]
Psychiatr Pol. 2011 Nov-Dec;45(6):875-88.
6
Magnetic resonance spectroscopy studies of the glutamatergic system in mood disorders: a pathway to diagnosis, novel therapeutics, and personalized medicine?情绪障碍中谷氨酸能系统的磁共振波谱研究：通往诊断、新型治疗方法和个性化医疗的途径？
Biol Psychiatry. 2010 Nov 1;68(9):780-2. doi: 10.1016/j.biopsych.2010.09.011.
7
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.三突触谷氨酸能突触在心境障碍的病理生理学和治疗学中的作用。
Neuroscientist. 2009 Oct;15(5):525-39. doi: 10.1177/1073858409336093. Epub 2009 May 26.
8
Glutamatergic modulators: the future of treating mood disorders?谷氨酸能调节剂：治疗心境障碍的未来？
Harv Rev Psychiatry. 2010 Sep-Oct;18(5):293-303. doi: 10.3109/10673229.2010.511059.
9
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.谷氨酸和γ-氨基丁酸系统作为新型抗抑郁和情绪稳定治疗的靶点。
Mol Psychiatry. 2002;7 Suppl 1:S71-80. doi: 10.1038/sj.mp.4001021.
10
Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.以谷氨酸能信号传导为靶点开发情绪障碍的新型疗法。
Curr Pharm Des. 2009;15(14):1595-611. doi: 10.2174/138161209788168010.
引用本文的文献
1
The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users.新型非竞争性 NMDA 受体拮抗剂依他佐辛（REL-1017）在娱乐性药物使用者中没有明显的滥用潜力。
Transl Psychiatry. 2023 Jun 7;13(1):192. doi: 10.1038/s41398-023-02473-8.
2
Esmethadone-HCl (REL-1017): a promising rapid antidepressant.依他佐辛盐酸盐（REL-1017）：一种有前途的快速抗抑郁药。
Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1463-1476. doi: 10.1007/s00406-023-01571-4. Epub 2023 Mar 8.
3
Authors' Reply to Pappagallo et al.: Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".作者对帕帕加洛等人的回复：对“用于治疗情绪障碍的新型谷氨酸能调节剂：现状”的评论
CNS Drugs. 2022 Feb;36(2):205-206. doi: 10.1007/s40263-021-00892-z. Epub 2022 Jan 11.
本文引用的文献
1
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.新型谷氨酸能调节剂治疗心境障碍的研究进展
CNS Drugs. 2021 May;35(5):527-543. doi: 10.1007/s40263-021-00816-x. Epub 2021 Apr 26.
2
Mu opioids and their receptors: evolution of a concept.μ 阿片类药物及其受体：概念的演变。
Pharmacol Rev. 2013 Sep 27;65(4):1257-317. doi: 10.1124/pr.112.007138. Print 2013.
3
Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study.在初级保健中从消旋美沙酮转为（R）-美沙酮的可行性和安全性：一项开放研究的临床结果。
World J Biol Psychiatry. 2009;10(3):217-24. doi: 10.1080/15622970802416057.
4
The addiction liability of some drugs of the methadon series.美沙酮系列某些药物的成瘾倾向
J Pharmacol Exp Ther. 1948 Jul;93(3):305-13.
5
Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat.吗啡、羟考酮、美沙酮及其对映体在大鼠不同伤害感受模型中的研究
Anesth Analg. 2006 Jun;102(6):1768-74. doi: 10.1213/01.ane.0000205751.88422.41.
6
Synthetic substances with morphine-like effect: clinical experience; potency, side-effects, addiction liability.具有吗啡样作用的合成物质：临床经验；效能、副作用、成瘾倾向。
Bull World Health Organ. 1957;17(4-5):569-863.
7
The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord.
Neurosci Lett. 1997 Feb 14;223(1):5-8. doi: 10.1016/s0304-3940(97)13391-2.
Zotero 插件